BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19182832)

  • 1. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.
    Tse WT; Duerst R; Schneiderman J; Chaudhury S; Jacobsohn D; Kletzel M
    Bone Marrow Transplant; 2009 Aug; 44(3):145-56. PubMed ID: 19182832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
    Kletzel M; Jacobsohn D; Duerst R
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
    Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
    Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
    Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
    Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
    Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
    Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
    Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
    Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
    Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
    Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
    Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
    Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
    Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population: a comparative study between the standard 4-dose and a 2-dose regimen.
    Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringdén O; Hassan M
    Bone Marrow Transplant; 2008 Apr; 41(7):621-5. PubMed ID: 18084338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
    Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
    Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
    Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
    Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.
    Chattergoon DS; Saunders EF; Klein J; Calderwood S; Doyle J; Freedman MH; Koren G
    Bone Marrow Transplant; 1997 Sep; 20(5):347-54. PubMed ID: 9339748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.
    Nguyen L; Leger F; Lennon S; Puozzo C
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):191-8. PubMed ID: 16133536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
    Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
    Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring.
    Mamlouk K; Saracino G; Berryman RB; Fay JW; Pineiro LA; Vance EA; White M; Sandler I; Agura ED
    Bone Marrow Transplant; 2005 Apr; 35(8):747-54. PubMed ID: 15750611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
    Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.
    Nguyen L; Fuller D; Lennon S; Leger F; Puozzo C
    Bone Marrow Transplant; 2004 May; 33(10):979-87. PubMed ID: 15064687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.